CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Virtual Care and Remote Automated MonitoringWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug2027 Rapid detection test Wiki 1.00
drug2364 Stool collection Wiki 1.00
drug1575 Nasopharyngeal swab Wiki 0.58

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Post Discharge After Surgery Virtual Care With Remote Automated Monitoring Technology (PVC-RAM) Trial

The Post discharge after surgery Virtual Care with Remote Automated Monitoring technology (PVC-RAM) Trial is a multicentre, parallel group, superiority, randomized controlled trial to determine the effect of virtual care with remote automated monitoring (RAM) technology compared to standard care on days alive at home during the 30-day follow-up after randomization, in adults who have undergone semi-urgent (e.g., oncology), urgent (e.g., hip fracture), or emergency (e.g., ruptured abdominal aortic aneurysm) surgery. It will also determine, during the first 30 days, the effect of virtual care with RAM technology on several secondary outcomes, including: 1. hospital re-admission; 2. emergency department visit; 3. urgent-care centre visit; 4. acute-hospital care (i.e., a composite of hospital re-admission and emergency department or urgent-care centre visit) 5. brief acute-hospital care (i.e., acute-hospital care that lasts <24 hours); 6. all-cause hospital days; 7. COVID-19 infection; 8. medication error detection; 9. medication error correction; 10. delirium; 11. surgeon, family physician, or specialist in-person clinic visit; 12. surgeon, family physician, or specialist virtual clinic visit; 13. sepsis; 14. acute heart failure; and 15. death. An additional secondary objective is to determine the effect of virtual care with RAM technology on pain at 7, 15, and 30 days and 6 months after randomization.

NCT04344665 Surgery Perioperative Complication COVID Other: Virtual Care and Remote Automated Monitoring

Primary Outcomes

Description: Days alive at home are the number of days patients spend at their usual residence - be it a house or apartment, a group home or shelter, a seniors residence, or a nursing home - or at a community residence of a relative, friend, or acquaintance without, during that day, being admitted to a hospital or visiting an emergency department or urgent-care centre. Thus, patients lose days alive at home if 1. patients go to an emergency department or urgent-care centre; 2. they become inpatients at a hospital or rehabilitation or convalescence-care facility; or 3. they die.

Measure: Days alive at home

Time: 30 Days (after randomization); 6 months (after randomization)

Secondary Outcomes

Measure: Hospital re-admission

Time: 30 Days (after randomization); 6 months (after randomization)

Measure: Emergency Department visit

Time: 30 Days (after randomization); 6 months (after randomization)

Measure: Urgent Care centre visit

Time: 30 Days (after randomization); 6 months (after randomization)

Measure: COVID-19 Infection

Time: 30 Days (after randomization); 6 months (after randomization)

Measure: Brief acute hospital care

Time: 30 Days (after randomization); 6 months (after randomization)

Description: Medication errors include mistakes in medication prescribing, transcribing, dispensing, administering, or monitoring due to preventable events or actions taken by a patient, caregiver, or healthcare worker. Medication errors include: drug omission (i.e., patient did not take a drug they were supposed to take), drug commission (i.e., patient taking a drug they were not supposed to take), duration error, dosing error, frequency error, route error, and timing error. We will record all drug errors identified and also report whether they resulted in harm.

Measure: Medication error detection

Time: Days 1, 7, 8, 15, 22 and 30 Days (after randomization in the intervention arm), 30 Days (after randomization in the standard care arm and collected on day 31)

Description: Any medication error that is corrected.

Measure: Medication error correction

Time: Days 1, 7, 8, 15, 22 and 30 Days (after randomization in the intervention arm), 30 Days (after randomization in the standard care arm and collected on day 31)

Measure: Delirium

Time: 30 Days (after randomization); 6 months (after randomization)

Measure: Surgeon, family physician, or specialist in-person clinic visit

Time: 30 Days (after randomization); 6 months (after randomization)

Measure: Surgeon, family physician, or specialist virtual visit

Time: 30 Days (after randomization); 6 months (after randomization)

Measure: Sepsis

Time: 30 Days (after randomization); 6 months (after randomization)

Measure: Acute Heart Failure

Time: 30 Days (after randomization); 6 months (after randomization)

Description: All cause mortality

Measure: Death

Time: 30 Days (after randomization); 6 months (after randomization)

Description: Assessed using the Brief Pain Inventory Short Form (BPI-SF)

Measure: Participant Pain

Time: 7 Days (after randomization)

Description: Assessed using the Brief Pain Inventory Short Form (BPI-SF)

Measure: Participant Pain

Time: 15 Days (after randomization)

Description: Assessed using the Brief Pain Inventory Short Form (BPI-SF)

Measure: Participant Pain

Time: 30 Days (after randomization); 6 months (after randomization)

Description: Composite of hospital re-admission and emergency department or urgent-care centre visit

Measure: Acute hospital care

Time: 30 Days (after randomization); 6 months (after randomization)

Description: If a patient is admitted to the hospital for any reason anytime between midnight and 23:59 on a given day, this will count as a day in hospital.

Measure: All-cause hospital days

Time: 30 Days (after randomization); 6 months (after randomization)

Other Outcomes

Description: Data on hospital re-admission, healthcare utilization, and costs of health service utilization will be obtained from the Institute for Clinical Evaluative Sciences (ICES) data repository

Measure: Health services utilization-related costs

Time: 30 Days (after randomization); 6 months (after randomization)

Description: Assessment performed using the Ambulatory Home Care Record

Measure: Patient level cost of recovery

Time: 30 Days (after randomization)

Description: Any surgical procedure undertaken for any reason (e.g., wound dehiscence, infection)

Measure: Re-operation

Time: 30 Days (after randomization); 6 months (after randomization)

Description: Arrythmia resulting in electrical cardioversion

Measure: Arrythmia resulting in electrical cardioversion

Time: 30 Days (after randomization); 6 months (after randomization)

Description: Acute renal failure resulting in dialysis

Measure: Acute renal failure resulting in dialysis

Time: 30 Days (after randomization); 6 months (after randomization)

Description: Patient intubated or put on bilevel positive airway pressure (BiPAP).

Measure: Respiratory failure

Time: 30 Days (after randomization); 6 months (after randomization)

Description: Infection

Measure: Infection

Time: 30 Days (after randomization); 6 months (after randomization)

Measure: Surgical site infection

Time: 30 Days (after randomization); 6 months (after randomization)

Measure: Life-threatening bleed

Time: 30 Days (after randomization); 6 months (after randomization)

Measure: Major bleed

Time: 30 Days (after randomization); 6 months (after randomization)

Measure: Critical organ bleed

Time: 30 Days (after randomization); 6 months (after randomization)

Measure: Ileus

Time: 30 Days (after randomization); 6 months (after randomization)

Measure: Myocardial Infarction

Time: 30 Days (after randomization); 6 months (after randomization)

Measure: Clinically important atrial fibrillation

Time: 30 Days (after randomization); 6 months (after randomization)

Measure: Symptomatic proximal venous thrombo-embolism

Time: 30 Days (after randomization); 6 months (after randomization)

Measure: Stroke

Time: 30 Days (after randomization); 6 months (after randomization)

Measure: Non-fatal cardiac arrest

Time: 30 Days (after randomization); 6 months (after randomization)

Measure: Clostridium difficile-associated diarrhea

Time: 30 Days (after randomization); 6 months (after randomization)

Measure: Indwelling device

Time: 30 Days (after randomization); 6 months (after randomization)


No related HPO nodes (Using clinical trials)